Role of Plasma Osteopontin Level as a Predictor of Hepatic Fibrosis Regression and Response to Antiviral Treatment in Patients with Chronic HBV or Chronic HCV Infection
Background: Hepatitis B virus and Hepatitis C virus infection is one of the public health problems in Egypt. So we aimed to evaluate the efficacy of serum osteopontin as predictor of hepatic fibrosis regression and virological response in patients with chronic HBV or HCV infection. Methods: This study has been conducted on 74 HBeAg + ve chronic HBV infection, 74 chronic HCV infection and 74 healthy controls. HBV patients treated with Entecavir. HCV patients treated with sofosbuvir, daclatasvir with or without ribavirin. One year post HBeAg seroconversion and 3 months after end of regular antiviral treatment for patients with chronic HBV and chronic HCV infection respectively, hepatic condition was reevaluated. Results: 14.9% of patients with HBV, failed to achieve undetectable HBV DNA or HBeAg seroconversion and 2.7% of patients with HCV infection, failed to achieve SVR. In chronic HBV, pretreatment high serum osteopontin predict failure of virological response and hepatic fibrosis regression at a cutoff > 115.5, with 90.91% sensitivity, 82.54% specificity. Also high degree of liver stiffness predicts failure of hepatic fibrosis regression at a cutoff > 8.7, with 81.8% sensitivity, 73% specificity. Conclusions: In chronic HBV infection low osteopontin predicts good virological response and hepatic fibrosis regression. But it has no role in predicting SVR or hepatic fibrosis regression in chronic HCV infected patients.
References
[1]
Kouyoumjian, S.P., Chemaitelly H. and Abu-Raddad, L.J. (2018) Characterizing Hepatitis C Virus Epidemiology in Egypt: Systematic Reviews, Meta-Analyses, and Meta-Regressions. Scientific Reports, 8, Article No. 1661. https://doi.org/10.1038/s41598-017-17936-4
[2]
Westbrook, R.H. and Dusheiko, G. (2014) Natural History of Hepatitis C. Journal of Hepatology, 61, S58-S68. https://doi.org/10.1016/j.jhep.2014.07.012
[3]
Abdel-Moneim, A., Aboud, A., Abdel-Gabaar, M., Zanaty, M.I. and Ramadan, M. (2018) Efficacy and Safety of Sofosbuvir Plus Daclatasvir with or without Ribavirin: Large Real-Life Results of Patients with Chronic Hepatitis C Genotype 4. Hepatology International, 12, 348-335. https://doi.org/10.1007/s12072-018-9868-8
[4]
Omar, H., et al. (2018) Generic Daclatasvir Plus Sofosbuvir, with or without Ribavirin, in Treatment of Chronic Hepatitis C: Real-World Results from 18 378 Patients in Egypt. Alimentary Pharmacology & Therapeutics, 47, 421-431. https://doi.org/10.1111/apt.14428
[5]
Mohamed, M.S., Hanafy, A.S., Bassiony, M.A.A. and Hussein, S. (2017) Sofosbuvir and Daclatasvir Plus Ribavirin Treatment Improve Liver Function Parameters and Clinical Outcomes in Egyptian Chronic Hepatitis C Patients. European Journal of Gastroenterology & Hepatology, 29, 1368-1372. https://doi.org/10.1097/MEG.0000000000000963
[6]
Ismail, S.A., et al. (2017) Hepatitis B in Egypt: A Cross-Sectional Analysis of Prevalence and Risk Factors for Active Infection from a Nationwide Survey. Liver International, 37, 1814-1822. https://doi.org/10.1111/liv.13469
[7]
Lai, C.L., Ratziu, V., Yuen, M.F. and Poynard, T. (2003) Viral Hepatitis B. The Lancet, 362, 2089-2094. https://doi.org/10.1016/S0140-6736(03)15108-2
[8]
Pawlotsky, J.M., et al. (2008) Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach. Gastroenterology, 134, 405-415. https://doi.org/10.1053/j.gastro.2007.11.036
[9]
Zhang, Q.Q., et al. (2011) Long-Term Nucleos(t)ide Analogues Therapy for Adults with Chronic Hepatitis B Reduces the Risk of Long-Term Complications: A Meta-Analysis. Virology Journal, 8, 72. https://doi.org/10.1186/1743-422X-8-72
[10]
Maklad, S., Reyad, E. M., William, E. A. and Abouzeid A. (2018) Effcacy and Safety of Entecavir 0.5 mg in Treating Naïve Chronic Hepatitis B Virus Patients in Egypt: Five Years of Real Life Experience. Gastroenterology Research, 11, 138-144. https://doi.org/10.14740/gr965w
[11]
Biçer, K.Ç., Ari, A., Genç, V.E., Caymaz, S.Ö., Avci, M. and Bal, F. (2015) Efficacy of Entecavir Treatment among Chronic Hepatitis B Nucleos(t)ide-Naive and -Experienced Patients. Turkish Journal of Medical Sciences, 45, 99-104. https://doi.org/10.3906/sag-1309-78
[12]
Choi, H.N., Song, J.E., Lee, H.C., Jo, H.H., Lee, C.H. and Kim, B.S. (2015) Efficacy of Prolonged Entecavir Monotherapy in Treatment-Naive Chronic Hepatitis B Patients Exhibiting a Partial Virologic Response to Entecavir. Clinical and Molecular Hepatology, 21, 24-31. https://doi.org/10.3350/cmh.2015.21.1.24
[13]
Senger, D.R., Wirth, D.F. and Hynes, R.O. (1979) Transformed Mammalian Cells Secrete Specific Proteins and Phosphoproteins. Cell, 16, 885-893. https://doi.org/10.1016/0092-8674(79)90103-X
[14]
Brown, L.F., Berse, B., Van de Water, L., Papadopoulos-Sergiou, A., Perruzzi, C.A., Manseau, E.J., et al. (1992) Expression and Distribution of Osteopontin in Human Tissues: Widespread Association with Luminal Epithelial Surfaces. Molecular Biology of the Cell, 3, 1169-1180. https://doi.org/10.1091/mbc.3.10.1169
[15]
Kawashima, R., et al. (1999) Expression of Osteopontin in Kupffer Cells and Hepatic Macrophages and Stellate Cells in Rat Liver after Carbon Tetrachloride Intoxication: A Possible Factor for Macrophage Migration into Hepatic Necrotic Areas. Biochemical and Biophysical Research Communications, 256, 527-531. https://doi.org/10.1006/bbrc.1999.0372
[16]
Srungaram, P., Rule, J.A., Yuan, H.J., Reimold, A., Dahl, B., Sanders, C., et al. (2015) Plasma Osteopontin in Acute Liver Failure. Cytokine, 73, 270-276. https://doi.org/10.1016/j.cyto.2015.02.021
[17]
Yilmaz, Y., et al. (2013) Serum Osteopontin Levels as a Predictor of Portal Inflammation in Patients with Nonalcoholic Fatty Liver Disease. Digestive and Liver Disease, 45, 58-62. https://doi.org/10.1016/j.dld.2012.08.017
[18]
Patouraux, S., Bonnafous, S., Voican, C.S., Anty, R., Saint-Paul, M.C., Rosenthal-Allieri, M.A., et al. (2012) The Osteopontin Level in Liver, Adipose Tissue and Serum is Correlated with Fibrosis in Patients with Alcoholic Liver Disease. PLoS ONE, 7, e35612. https://doi.org/10.1371/journal.pone.0035612
[19]
Zhao, L., Li, T., Wang, Y., Pan, Y., Ning, H., Hui, X., et al. (2008) Elevated Plasma Osteopontin Level Is Predictive of Cirrhosis in Patients with Hepatitis B Infection. International Journal of Clinical Practice, 62, 1056-1062. https://doi.org/10.1111/j.1742-1241.2007.01368.x
[20]
Matsue, Y., Tsutsumi, M., Hayashi, N., Saito, T., Tsuchishima, M., Toshikuni, N., et al. (2015) Serum Osteopontin Predicts Degree of Hepatic Fibrosis and Serves as a Biomarker in Patients with Hepatitis C Virus Infection. PLoS ONE, 10, e0118744. https://doi.org/10.1371/journal.pone.0118744
[21]
Shang, S., Plymoth, A., Ge, S., Feng, Z., Rosen, H.R., Sangrajrang, S., et al. (2012) Identification of Osteopontin as a Novel Marker for Early Hepatocellular Carcinoma. Hepatology, 55, 483-490. https://doi.org/10.1002/hep.24703
[22]
Friedman, S.L. (2000) Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury. The Journal of Biological Chemistry, 275, 2247-2250. https://doi.org/10.1074/jbc.275.4.2247
[23]
European Association for the Study of the Liver (2017) EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. Journal of Hepatology, 67, 370-398. https://doi.org/10.1016/j.jhep.2017.03.021
[24]
European Association for the Study of the Liver (2015) EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatology, 63, 199-236. https://doi.org/10.1016/j.jhep.2015.03.025
[25]
Denda, S., Reichardt, L.F. and Muller, U. (1998) Identification of Osteopontin as a Novel Ligand for the Integrin α8β1 and Potential Roles for this Integrin-Ligand Interaction in Kidney Morphogenesis. Molecular Biology of the Cell, 9, 1425-1435. https://doi.org/10.1091/mbc.9.6.1425
[26]
Pereira, T.A., Syn, W.K. Machado, M.V., Vidigal, P.V., Resende, V., Voieta, I., et al. (2015) Schistosome-Induced Cholangiocyte Proliferation and Osteopontin Secretioncorrelate with Fibrosis and Portal Hypertension in Human and Murineschistosomiasis Mansoni. Clinical Science, 129, 875-883. https://doi.org/10.1042/CS20150117
[27]
Gai, X.-D. and Wu, W.-F. (2017) Effect of Entecavir in the Treatment of Patients with Hepatitis Bvirus‑Related Compensated and Decompensated Cirrhosis. Experimental and Therapeutic Medicine, 14, 3908-3914. https://doi.org/10.3892/etm.2017.4963
[28]
Mehrez, M.I., Saleh, M.A. and Fareid, A. (2017) Fibrosis Regression after Treatment with Daas. Gastroenterology & Hepatology: Open Access (GHOA), 7, 00223. https://doi.org/10.15406/ghoa.2017.07.00223
[29]
Shousha, H.I., Mehassab, M.K., Mehrez, M.I., Afifi, S.A, Elsharkawy, M., Hamed, M. and Abdelaziz, R.A. (2017) Non-Invasive Fibrosis Scores and Liver Stiffness Changes in Chronic Hepatitis C after Sofosbuvir-Based Treatment. International Journal of Hepatology & Gastroenterology, 3, 85-90.
[30]
Mousa, O.Y., Kim, C.H., Pham, L.E., Zela, S.A., Egwim, C. and Sey, V.A. (2017) Predictors of Sustained Virologic Response and Failure of First DAA Terapy in Chronic Hepatitis C Patients. SM Journal of Hepatitis Research and Treatment, 3, 10-14.
[31]
Ahmed, O.A., et al. (2018) Outcomes and Predictors of Treatment Response with Sofosbuvir plus Daclatasvir with or without Ribavirin in Egyptian Patients with Genotype 4 Hepatitis C Virus Infection. Infection and Drug Resistance, 11, 441-445. https://doi.org/10.2147/IDR.S160593
[32]
Khan, S.T., McGuinty, M., Corsi, D.J. and Cooper, C.L. (2017) Liver Enzyme Normalization Predicts Success of Hepatitis C Oral Direct Acting Antiviral Treatment. Clinical and Investigative Medicine, 40, E73-E80. https://doi.org/10.25011/cim.v40i2.28198
[33]
Myung, H.J., Jeong, S.H., Kim, J.W., Kim, H.S., Jang, J.H., Lee, D.H., Kim, N., Hwang, J.H., Park, Y.S. and Lee, S.H. (2010) Efficacy and Predictors of the Virologic Response to Entecavir Therapy in Nucleoside-Naive Patients with Chronic Hepatitis B. The Korean Journal of Hepatology, 16, 57-65. https://doi.org/10.3350/kjhep.2010.16.1.57
[34]
Huang, Y.-J., Chang, C.-S., Peng, Y.-C., Yeh, H.-Z. and Yang, S.-S. (2017) On-Treatment HBV DNA Dynamics Predict Virological Breakthrough in Entecavir-Treated HBeAg-Positive Chronic Hepatitis B. PLoS ONE, 12, e0174046. https://doi.org/10.1371/journal.pone.0174046
[35]
Choi, S.S., Claridge, L.C., Jhaveri, R., Swiderska-Syn, M., Clark, P., Suzuki, A., et al. (2014) Osteopontin Is Up-Regulated in Chronic Hepatitis C and Is Associated with Cellular Permissiveness for Hepatitis C Virus Replication. Clinical Science, 126, 845-855. https://doi.org/10.1042/CS20130473
[36]
Iqbal, J., McRae, S., Banaudha, K., Mai, T. and Waris, G. (2013) Mechanism of Hepatitis C Virus (HCV) -Induced Osteopontin and Its Role in Epithelial to Mesenchymal Transition of Hepatocytes. Journal of Biological Chemistry, 288, 36994-37009. https://doi.org/10.1074/jbc.M113.492314
[37]
Liu, L., Lu, J., Ye, C., Lin, L., Zheng, S., Zhang, H., Lan, Q. and Xue, Y. (2018) Serum Osteopontin Is a Predictor of Prognosis for HBV-Associated Acute-on-Chronic Liver Failure. Biomedical Reports, 8, 166-171.
[38]
Chon, Y.E., et al. (2017) Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients with Advanced Fibrosis. The American Journal of Gastroenterology, 112, 882-891. https://doi.org/10.1038/ajg.2017.93
